In this issue:
Predicting outcomes in ibrutinib-treated CLL
Long-term survival with blinatumomab in R/R ALL
Azacitidine maintenance vs observation post-transplant in AML and MDS
Chemotherapy after anti-PD-1 failure in R/R Hodgkin lymphoma
Anti-CD30 CAR-T cell therapy R/R Hodgkin lymphoma
Ivosidenib plus azacitidine in newly diagnosed AML
Obinutuzumab, ibrutinib, + venetoclax in CLL
Outcomes after stopping TKIs in CML
CPX-351 in AML at high risk for induction mortality
Please login below to download this issue (PDF)